Core Insights - Windward Bio AG has announced a licensing agreement with Qyuns Therapeutics for the development and commercialization of WIN027, a bispecific antibody targeting TSLP and IL-13, which is expected to enhance treatment for advanced immunological diseases [1][2][3] Group 1: Licensing Agreement Details - The agreement grants Windward Bio exclusive rights to develop, manufacture, and commercialize WIN027 outside of China, with a total deal value of up to $700 million, including upfront payments, equity, and milestone payments contingent on specific achievements [2] - The licensing deal is part of Windward Bio's strategy to expand its immunology pipeline and accelerate the development of differentiated therapies for serious immunological diseases [3] Group 2: Product Information - WIN027 is a humanized IgG1 bispecific monoclonal antibody with subpicomolar affinity for TSLP and IL-13, designed for long-acting inhibition and less frequent dosing, targeting conditions such as asthma, COPD, and atopic dermatitis [4][7] - WIN378, another product in Windward Bio's pipeline, is a long-acting anti-TSLP monoclonal antibody currently in Phase 2 trials for asthma, with initial data expected in 2026 [3][5] Group 3: Market Opportunity - The combined market opportunity for WIN027 and WIN378 is estimated to exceed $50 billion, addressing significant unmet needs across a range of immunological diseases [3]

Group 1 - The core point of the article is that Qianxin Bio-B (02509.HK) has entered into a licensing and collaboration agreement with Windward BioGroup AG's subsidiary LE2025 Therapeutics AG, granting LE2025 exclusive rights to develop and commercialize QX027N in specified regions outside of mainland China, Taiwan, Hong Kong, and Macau [1] - The agreement allows Qianxin Bio to receive up to $700 million in total payments, which includes an upfront payment, equity from Windward Bio, development and commercial milestone payments, and tiered royalties based on net sales of QX027N in the licensed regions [1] Group 2 - Windward Bio is a clinical-stage biotechnology company with expertise in discovery, development, and commercialization, focused on transforming treatment for patients with advanced immune diseases [2] - Windward Bio's leading project is WIN378, a potential best-in-class long-acting anti-TSLP monoclonal antibody currently undergoing Phase II clinical trials for asthma [2] - The company's research pipeline also includes WIN027, a long-acting dual-specific antibody targeting TSLP and IL-13, which has potential applications across various immune diseases [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全 部 或 任 何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Qyuns Therapeutics Co., Ltd. 江蘇荃信生物醫藥股份有限公司 （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號：2509） 自願公告 與WINDWARD BIO GROUP AG附屬公司 就QX027N的開發及 商業化簽訂許可及合作協議 有 關QX027N QX027N是本公司自主研發的長效 抗TSLPxIL-13 雙 特 異 性 抗 體。誠 如2025年11月13 日的自願公告所述，QX027N已獲得國家藥品監督管理局藥品審評中心的臨床試驗 默 示 許 可（受 理 號：CXSL2500757，CXSL2500758），擬 用 於 治 療 哮 喘 及 特 應 性 皮 炎。 於2025年12月12日，本公司成功啟動QX027N的I期臨床試驗，在中國 完成首例受試 者入組。 – ...